Autor según el artículo: Salas-Salvadó, J. for the PREDIMED Study Investigators. Sorli, J.V. Covas, M.I. Serra-Majem, L. Estruch, R. Ortega-Calvo, M. Salaverría, I. Wärnberg, J. Martínez-González, M.Á. Bulló, M. Ibarrola-Jurado, N. Babio, N.

Versión del articulo depositado: info:eu-repo/semantics/publishedVersion

Enlace a la fuente original: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0058354

Departamento: Bioquímica i Biotecnologia Ciències Mèdiques Bàsiques

Autor/es de la URV: Nancy Babio, Nuria ibarrola, Mónica Bulló, Miguel Ángel Martínez-González

DOI del artículo: 10.1371/journal.pone.0058354

Resumen: The Metabolic Syndrome (MetS) is a cluster of metabolic abnormalities that includes hyperglucemia, hypertension, dyslipidemia and central obesity, conferring an increased risk of cardiovascular disease. The white blood cell (WBC) count has been proposed as a marker for predicting cardiovascular risk. However, few prospective studies have evaluated the relationship between WBC subtypes and risk of MetS. Participants were recruited from seven PREDIMED study centers. Both a baseline cross-sectional (n = 4,377) and a prospective assessment (n = 1,637) were performed. Participants with MetS at baseline were excluded from the longitudinal analysis. The median follow-up was 3.9 years. Anthropometric measurements, blood pressure, fasting glucose, lipid profile and WBC counts were assessed at baseline and yearly during the follow-up. Participants were categorized by baseline WBC and its subtype count quartiles. Adjusted logistic regression models were fitted to assess the risk of MetS and its components.

Entidad: Universitat Rovira i Virgili.

Año de publicación de la revista: 2013

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 1932-6203

Volumen de revista: 8